PROZAC WEEKLY

Compare PROZAC WEEKLY  to:
Compare
Compare

Generic Name for PROZAC WEEKLY

Fluoxetine (as HCl) 90mg; caps containing e-c delayed-release pellets.

Legal Classification:

Rx

Pharmacological Class for PROZAC WEEKLY

SSRI.

Manufacturer of PROZAC WEEKLY

Dista Products Company

Indications for PROZAC WEEKLY

Maintenance phase of depression.

Adult dose for PROZAC WEEKLY

90mg once weekly. Start 7 days after last dose of fluoxetine 20mg (when switching from daily dosing).

Children's dosing for PROZAC WEEKLY

Not recommended.

Also:

Contraindications for PROZAC WEEKLY

During or within 14 days of MAOIs. Concomitant pimozide, thioridazine (may cause QTc prolongation).

Precautions for PROZAC WEEKLY

Monitor for serotonin syndrome or neuroleptic malignant syndrome-like signs/symptoms; discontinue if occurs. Discontinue if unexplained allergic reaction occurs. Renal or hepatic dysfunction. History of seizures or mania/hypomania. Recent MI. Unstable heart disease. ECT (prolonged seizures). Reevaluate periodically in long-term use. Avoid abrupt cessation. Monitor weight. Conditions that affect metabolism or hemodynamic responses. Volume depletion. Diabetes. Suicidal tendencies (monitor). Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C; avoid 3rd trimester or consider lower dose; see literature for effects on neonate). Nursing mothers: not recommended.

Interactions for PROZAC WEEKLY

See Contraindications. Do not start MAOI or thioridazine within at least 5 weeks of discontinuing fluoxetine. Concomitant SSRIs, SNRIs, tryptophan: not recommended. May potentiate protein-bound drugs (eg, warfarin, digoxin) and those metabolized by CYP2D6 (eg, tricyclics, vinblastine, flecainide). May potentiate carbamazepine, phenytoin. Monitor lithium, phenytoin, warfarin, tricyclics. Caution with benzodiazepines (eg, diazepam, alprazolam), antipsychotics (eg, clozapine, haloperidol), other CNS drugs. Increased risk of bleeding with NSAIDs, aspirin, warfarin, others that affect coagulation. Caution with triptans, linezolid, lithium, tramadol, St. John's wort; may cause serotonin syndrome (eg, weakness, incoordination, hyperreflexia). Hyponatremia with diuretics.

Adverse Reactions for PROZAC WEEKLY

Nausea, CNS stimulation (eg, anxiety, nervousness, insomnia), somnolence, headache, mania/hypomania, anorexia, weight loss, tremor, asthenia, sexual dysfunction, sweating, GI disturbances, respiratory symptoms, motor impairment, serum sickness, hypo- or hyperglycemia, rash (may be serious), urticaria, pruritus; rarely: platelet dysfunction. Children: thirst, hyperkinesia, agitation, personality disorder, epistaxis, urinary frequency, menorrhagia.

How is PROZAC WEEKLY supplied?

Caps 10mg—100
20mg—30, 100, 2000
40mg—30
Liq—4oz
Weekly—4

Related Disease:

Depression

Related Resources

Oleptro approved for major depressive disorder (MDD)

February 03, 2010

The FDA has approved Oleptro (trazodone HCl extended-release tablets, from Labopharm), a once-daily formulation of trazodone, for the treatment of major depressive disorder (MDD) in adults.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Seroquel XR approved for adjunctive treatment of major depressive disorder (MDD)

December 07, 2009

Seroquel XR (quetiapine fumarate extended-release tablets, from AstraZeneca) has been approved by the FDA as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD).

Zyprexa approved for schizophrenia and bipolar I disorder in adolescents

December 07, 2009

The FDA has approved Zyprexa (olanzapine, from Lilly) tablets for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents 13-17 years of age.

FDA warns of birth defects with valproate sodium, valproic acid, and divalproex sodium

December 03, 2009

The FDA has notified healthcare professionals and patients about the increased risk of neural tube defects and other major birth defects (eg, craniofacial defects and cardiovascular malformations) in babies exposed to valproate sodium and related products (valproic acid and divalproex sodium) during pregnancy.